Senseonics(NASDAQ) SENS

Senseonics Holdings, Inc. makes sensors that help people manage diabetes. These tiny devices track blood sugar levels automatically for several months. Patients avoid daily finger sticks and frequent sensor changes.

Long-Wear Glucose Sensors

• Eversense 365: Long-term implantable sensor providing glucose readings for up to one year; cleared for sale in the United States in Sept. 2024.
• Eversense E3: Six-month implantable monitoring system that uses sacrificial boronic acid technology to maintain accuracy over long periods.
• Gemini System: Next-generation monitoring product designed to combine continuous glucose readings with on-demand flash monitoring.
• Freedom System: Future sensor variation intended to utilize Bluetooth technology to eliminate the need for an on-body transmitter.

Strategic Commercial Moves

• Reassumed full responsibility for United States sales and marketing activities on Jan. 1, 2026.
• Closed the acquisition of commercial assets in Europe to manage direct distribution in select territories in June 2026.
• Obtained FDA approval for the 365-day Eversense system for all people with diabetes using insulin in Sept. 2024.
• Implemented a 1-for-20 reverse stock split of its common stock on Oct. 17, 2025.
• Launched a nurse practitioner network called Eon Care to support patient access to sensor insertion procedures.

Differentiation Through Longevity

Senseonics provides the only glucose sensor in the continuous monitoring category that stays in place during magnetic resonance imaging, or MRI, scans. These sensors last significantly longer than traditional systems, which typically require replacement every seven to 15 days.

Measuring the Financials

• Total revenue was $14.5 million for the three-month period ended June 30, 2026, with 86.8% of sales coming from the United States.
• Gross margin improved to 59.1% for the quarter ended June 30, 2026, compared to 46.9% in the prior-year period.
• Consignment sales through healthcare professionals accounted for 57.7% of total revenue during the second quarter of 2026.
• Unrestricted cash, cash equivalents, and marketable securities totaled $142.7 million as of June 30, 2026.
• Net loss was $69.0 million for the six-month period ended June 30, 2026, compared to $28.8 million in the first half of 2025.

The Evolution of Senseonics

Senseonics has transitioned from a research-focused organization into a commercial medical technology company. Its shift to direct sales and the launch of longer-wear sensors support its efforts to expand in the global diabetes market.